Evidence map›Paper›PMID 25073664›Full record

ArticleInternational journal of radiation oncology, biology, physics2014

Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma.

Andreas Rimner, Daniel E Spratt, Marjorie G Zauderer, Kenneth E Rosenzweig, Abraham J Wu, Amanda Foster, Ellen D Yorke, Prasad Adusumilli, Valerie W Rusch, Lee M Krug

Open access · greenAbstract read
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018
    Guideline
  2. The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2017
    Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Observational
  10. Article
  11. Progress in the Management of Malignant Pleural Mesothelioma in 2017.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2018
    Review
  12. Proton beam therapy for malignant pleural mesothelioma.Translational lung cancer research · 2018
    Review
  13. Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2017
    Article
  14. Review
  15. Does selective pleural irradiation of malignant pleural mesothelioma allow radiation dose escalation? : A planning study.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2017
    Article
  16. Article
  17. Local and systemic therapies for malignant pleural mesothelioma.Current treatment options in oncology · 2014
    Review
  18. Radioluminescence characterization ofApplied physics letters · 2014
    Article
  19. Malignant pleural mesothelioma - Pleural cavity irradiation after decortication with helical tomotherapy.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Andreas RimnerDepartment of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York. Electronic address: rimnera@mskcc.org.
Daniel E SprattDepartment of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York.
Marjorie G ZaudererDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center; Weill Cornell Medical College, New York, New York.
Kenneth E RosenzweigDepartment of Radiation Oncology, Mount Sinai Medical Center, New York, New York.
Abraham J WuDepartment of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York.
Amanda FosterDepartment of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York.
Ellen D YorkeDepartment of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York.
Prasad AdusumilliDepartment of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York.
Valerie W RuschDepartment of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York.
Lee M KrugDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center; Weill Cornell Medical College, New York, New York.
Memorial Sloan Kettering Cancer Center · USMount Sinai Medical Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeWe previously reported our technique for delivering intensity modulated radiation therapy (IMRT) to the entire pleura while attempting to spare the lung in patients with malignant pleural mesothelioma (MPM). Herein, we report a detailed pattern-of-failure analysis in patients with MPM who were unresectable or underwent pleurectomy/decortication (P/D), uniformly treated with hemithoracic pleural IMRT. METHODS AND MATERIALS: Sixty-seven patients with MPM were treated with definitive or adjuvant hemithoracic pleural IMRT between November 2004 and May 2013. Pretreatment imaging, treatment plans, and posttreatment imaging were retrospectively reviewed to determine failure location(s). Failures were categorized as in-field (within the 90% isodose line), marginal (<90% and ≥50% isodose lines), out-of-field (outside the 50% isodose line), or distant.

resultsThe median follow-up was 24 months from diagnosis and the median time to in-field local failure from the end of RT was 10 months. Forty-three in-field local failures (64%) were found with a 1- and 2-year actuarial failure rate of 56% and 74%, respectively. For patients who underwent P/D versus those who received a partial pleurectomy or were deemed unresectable, the median time to in-field local failure was 14 months versus 6 months, respectively, with 1- and 2-year actuarial in-field local failure rates of 43% and 60% versus 66% and 83%, respectively (P=.03). There were 13 marginal failures (19%). Five of the marginal failures (38%) were located within the costomediastinal recess. Marginal failures decreased with increasing institutional experience (P=.04). Twenty-five patients (37%) had out-of-field failures. Distant failures occurred in 32 patients (48%).

conclusionsAfter hemithoracic pleural IMRT, local failure remains the dominant form of failure pattern. Patients treated with adjuvant hemithoracic pleural IMRT after P/D experience a significantly longer time to local and distant failure than patients treated with definitive pleural IMRT. Increasing experience and improvement in target delineation minimize the incidence of avoidable marginal failures.

Indexed as

AgedCombined Modality TherapyFemaleFollow-Up StudiesHumansLung NeoplasmsLymphatic MetastasisMaleMesotheliomaMesothelioma, MalignantMiddle AgedOrgan Sparing TreatmentsPleuraPleural NeoplasmsRadiographyRadiotherapy, Intensity-Modulated

Identifiers

PMID25073664
PMCPMC5560169
OpenAlexW2054741823

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.